A Bayesian Decision-Theoretic Dose-Finding Trial

References

• Anscombe F. J. Sequential medical trials. J. Amer. Statist. Assoc. (1963) 58:365–383Crossref, Google Scholar
• Berry D. A. A case for Bayesianism in clinical trials (with discussion). Statist. Medicine (1993) 12:1377–1404Crossref, Google Scholar
• Berry D. A. Bayesian statistics and the efficiency and ethics of clinical trials. Statist. Sci. (2004) 19:175–187Crossref, Google Scholar
• Berry D. A. Bayesian clinical trials. Nature Rev. Drug Discovery (2006) 5:27–36Crossref, Google Scholar
• Berry D. A., Stangl D. K., Berry D. A., Stangl D. K. Bayesian methods in health related research. Bayesian Biostatistics (1996) (Dekker, New York) 3–66Crossref, Google Scholar
• Berry D. A., Müller P., Grieve A. P., Smith M., Parke T., Blazek R., Mitchard N., Krams M., Gatsonis C., Kass R. E., Carlin B., Carriquiry A., Gelman A., Verdinelli I., West M. Adaptive Bayesian designs for dose-ranging drug trials. Case Studies in Bayesian Statistics, Vol. V. Lecture Notes in Statistics (2001) (Springer-Verlag, New York) Google Scholar
• Berry S. M., Kadane J. B. Optimal Bayesian randomization. J. Roy. Statist. Soc.–B (1997) 59(4):813–819Crossref, Google Scholar
• Brockwell A. E., Kadane J. B. A gridding method for Bayesian sequential decision problems. J. Comput. Graphical Statist. (2003) 12:566–584Crossref, Google Scholar
• Carlin B. P., Kadane J. B., Gelfand A. E. Approaches for optimal sequential decision analysis in clinical trials. Biometrics (1998) 54:964–975Crossref, Google Scholar
• Carter C. K., Kohn R. On Gibbs sampling for state space models. Biometrika (1994) 81:541–553Crossref, Google Scholar
• Christen J. A., Müller P., Wathen K., Wolf J. A Bayesian randomized clinical trial: A decision-theoretic sequential design. Canadian J. Statist. (2004) 32(4):387–402Crossref, Google Scholar
• DeGroot M.Optimal Statistical Decisions (1970) (McGraw Hill, New York) Google Scholar
• Frühwirth-Schnatter S. Data augmentation and dynamic linear models. J. Time Series Anal. (1994) 15:183–202Crossref, Google Scholar
• Grieve A. P., Krams M. ASTIN: A Bayesian adaptive dose-response trial in acute stroke. Clinical Trials (2005) 2:340–351Crossref, Google Scholar
• Krams M., Lees K. R., Hacke W., Grieve A. P., Orgogozo J. M., Ford G. A. ASTIN: An adaptive dose-response study of UK-279, 276 in acute ischemic stroke. Stroke (2003) 34:2543–2548Crossref, Google Scholar
• Lees K. R., Diener H.-C., Asplund K., Krams M. UK 279, 276, a neutrophil inhibitory glycoprotein, in acute stroke: Tolerability and pharmacokinetics. Stroke (2003) 34:1704–1709Crossref, Google Scholar
• Müller P., Berry D. A., Grieve A., Smith M., Krams M. Simulation-based sequential Bayesian design. J. Statist. Plann. Inferrence (2006) . ForthcomingGoogle Scholar
• Robert C.The Bayesian Choice (2001) (Springer-Verlag, New York) Google Scholar
• Rossell D., Müller P., Rosner G. L. Screening designs for drug development. Biostatistics (2006) . ForthcomingGoogle Scholar
• Scandinavian Stroke Study Group Multicenter trial of hemodilution in ischemic stroke. Background and study protocol. Stroke (1985) 16:885–890Crossref, Google Scholar
• Spiegelhalter D. J., Abrams K. R., Myles J. P.Bayesian Approaches to Clinical Trails and Health Care Evaluation (2004) (John Wiley and Sons, Chichester, UK) Google Scholar
• Stallard N. Decision theoretic designs for phase II clinical trials allowing for competing studies. Biometrics (2003) 59:402–409Crossref, Google Scholar
• Thall P. F., Simon R. M., Estey E. H. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Statist. Medicine (1995) 14:357–379Crossref, Google Scholar
• West M., Harrison P. J.Bayesian Forecasting and Dynamic Models (1997) 2nd ed.(Springer-Verlag, New York) Google Scholar
• Yin G., Li Y., Ji Y. Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios. Biometrics (2006) 62(3):777–787Crossref, Google Scholar
• Zhang L., Zhang Z. G., Zhang R. L., Lu M., Krams M., Chopp M. Effects of a selective CD11b/CD18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke. Stroke (2003) 34:1790–1795Crossref, Google Scholar